Colimycin
Coly-mycin M (colimycin) is a protein pharmaceutical. Colimycin was first approved as Coly-mycin m on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Coly-mycin m (generic drugs available since 1999-02-26)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Colistimethate sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| COLY-MYCIN M | Par Pharmaceutical | N-050108 RX | 1982-01-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| colistimethate | ANDA | 2022-12-02 |
| coly-mycin | New Drug Application | 2018-12-03 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07A: Intestinal antiinfectives
— A07AA: Antibiotics, intestinal
— A07AA10: Colistin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01X: Other antibacterials in atc
— J01XB: Polymyxins
— J01XB01: Colistin
HCPCS
No data
Clinical
Clinical Trials
61 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | 2 | 8 | 1 | 1 | 10 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | 3 | 3 | 1 | 8 |
| Infections | D007239 | EFO_0000544 | — | — | 4 | 1 | 1 | 6 | |
| Acinetobacter infections | D000151 | EFO_1000792 | — | — | — | 1 | 3 | 4 | |
| Bacterial infections | D001424 | A49 | — | — | 2 | 1 | 1 | 4 | |
| Gram-negative bacterial infections | D016905 | — | — | — | 3 | — | 3 | ||
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | 1 | 1 | — | 2 | |
| Critical illness | D016638 | 1 | — | — | 1 | — | 2 | ||
| Communicable diseases | D003141 | — | — | 1 | 1 | — | 2 | ||
| Cross infection | D003428 | — | — | 1 | 1 | — | 2 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | — | 2 | — | 1 | 4 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | 1 | 2 | — | 1 | 3 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | 3 | ||
| Sepsis | D018805 | A41.9 | — | — | 1 | — | 1 | 2 | |
| Healthcare-associated pneumonia | D000077299 | — | 1 | 1 | — | — | 2 | ||
| Iatrogenic disease | D007049 | — | — | 1 | — | — | 1 | ||
| Bronchitis | D001991 | J40 | — | — | 1 | — | — | 1 | |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | 1 | — | — | 1 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | — | 1 | — | — | 1 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pseudomonas aeruginosa | D011550 | NCBITaxon_287 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumococcal infections | D011008 | EFO_0000772 | J13 | 1 | — | — | — | — | 1 |
| Pseudomonas infections | D011552 | EFO_0001076 | 1 | — | — | — | — | 1 | |
| Gram-negative bacteria | D006090 | 1 | — | — | — | — | 1 | ||
| Hepatic encephalopathy | D006501 | K72.91 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | COLIMYCIN |
| INN | colistimethate sodium |
| Description | Colistin, also known as polymyxin E, is an antibiotic medication used as a last-resort treatment for multidrug-resistant Gram-negative infections including pneumonia. These may involve bacteria such as Pseudomonas aeruginosa, Klebsiella pneumoniae, or Acinetobacter. It comes in two forms: colistimethate sodium can be injected into a vein, injected into a muscle, or inhaled, and colistin sulfate is mainly applied to the skin or taken by mouth. Colistimethate sodium is a prodrug; it is produced by the reaction of colistin with formaldehyde and sodium bisulfite, which leads to the addition of a sulfomethyl group to the primary amines of colistin. Colistimethate sodium is less toxic than colistin when administered parenterally. In aqueous solutions it undergoes hydrolysis to form a complex mixture of partially sulfomethylated derivatives, as well as colistin. Resistance to colistin began to appear as of 2015.
|
| Classification | Protein |
| Drug class | antibiotics (Streptomyces strain) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCC(C)CCCCC(=O)NCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 1066-17-7 |
| RxCUI | 2709 |
| ChEMBL ID | CHEMBL507048 |
| ChEBI ID | — |
| PubChem CID | 5311054 |
| DrugBank | DB00803 |
| UNII ID | XW0E5YS77G (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,601 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,614 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more